3-hydroxybenzylhydrazine has been researched along with Substance Withdrawal Syndrome in 1 studies
3-hydroxybenzylhydrazine: decarboxylase inhibitor; RN given refers to parent cpd; structure
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Abrupt nicotine cessation after chronic use disrupts monoaminergic systems and causes withdrawal signs/symptoms." | 1.37 | 5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal. ( Domino, EF; Jutkiewicz, EM; Ohmura, Y; Yoshioka, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohmura, Y | 1 |
| Jutkiewicz, EM | 1 |
| Yoshioka, M | 1 |
| Domino, EF | 1 |
1 other study available for 3-hydroxybenzylhydrazine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
5-Hydroxytryptophan attenuates somatic signs of nicotine withdrawal.
Topics: 5-Hydroxytryptophan; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Hydraz | 2011 |